AbsoluteDx Prostate Cancer
Use
AbsoluteDx Prostate Cancer analyzes clinically significant and actionable genes associated with prostate cancer. It integrates with Multi-Ancestry Prostate Cancer PRS to assess risk in non-carriers and modulate the expected penetrance for precise risk estimation.
Special Instructions
Test ordered through Allelica's secure platform. Non-invasive saliva sample collected for DNA extraction, shipped to Allelica’s CLIA, CAP laboratory for consideration.
Limitations
Relies on accurate identification and integration of monogenic mutations and polygenic risk. Estimates are subject to quality and accuracy of sequencing data and analytical models.
Methodology
NGS (WGS)
Biomarkers
Result Turnaround Time
3-4 weeks
Related Documents
For more information, please review the documents below
Specimen
Saliva
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Simple, non-invasive saliva sample collection